Valuation: Mymetics Corporation

Market Cap 4L 4L 4L 3L 6L 4.25Cr 6L 42.87L 16.72L 2.07Cr 16.47L 16.12L 7.19Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.34Cr 5.89Cr 5.42Cr 10Cr 698.45Cr 10Cr 70Cr 27Cr 340.67Cr 27Cr 26Cr 1.18TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+10,66,566.67%
Current month+10,66,566.67%
1 month+10,66,566.67%
3 months+10,66,566.67%
6 months+10,66,566.67%
Current year+10,66,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
31.01
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+10,66,566.67%+10,66,566.67%-90.36% 45
+1.23%+0.35%+51.62%+87.98% 5.59TCr
+1.33%+7.34%+63.40%+68.55% 5.67TCr
-2.85%-2.30%-21.99%-16.49% 2.33TCr
-0.68%-2.15%+2.39%+418.04% 2.33TCr
-0.36%-0.56%+36.00%-3.93% 2.05TCr
-1.34%+0.51%+25.02%-30.27% 1.78TCr
-1.44%-1.63%+37.07%+589.93% 1.59TCr
-1.30%-9.92%+160.67%+284.37% 1.46TCr
-0.22%-1.23%+23.31%+177.68% 1.4TCr
Average +3.98%+1.17%+1,06,694.42%+148.55% 2.42TCr
Weighted average by Cap. -0.07%+3.20%+43.29%+138.69%

Financials

2021 2022
Net sales 4L 4L 4L 3L 6L 4.16Cr 6L 42.01L 16.39L 2.03Cr 16.14L 15.79L 7.05Cr 10.28L 9L 8L 8L 14.49L 9.96Cr 14.75L 1Cr 39.18L 4.86Cr 38.59L 37.76L 17Cr
Net income -47.3L -41.6L -38.65L -35.54L -66.66L -46Cr -67.85L -4.62Cr -1.8Cr -22Cr -1.78Cr -1.74Cr -78Cr -48.05L -42.26L -39.26L -36.11L -67.71L -47Cr -68.93L -4.69Cr -1.83Cr -23Cr -1.8Cr -1.76Cr -79Cr
Net Debt 6.71Cr 5.9Cr 5.48Cr 5.04Cr 9.46Cr 649.81Cr 9.63Cr 66Cr 26Cr 316.95Cr 25Cr 25Cr 1.1TCr 7.17Cr 6.3Cr 5.86Cr 5.39Cr 10Cr 694.2Cr 10Cr 70Cr 27Cr 338.6Cr 27Cr 26Cr 1.17TCr
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
2
  1. Stock Market
  2. Stocks
  3. MYMX Stock